SLC5A2 and cardiovascular disorder: SGLT2 inhibitors reduce blood glucose via inhibiting the reabsorption of glucose by the proximal renal tubules, resulting in osmotic diuresis and glycosuria, and its mechanism of action is insulin-independent.[6,7] However, one of the adverse reactions of SGLT2 inhibitors is an increase in LDL-C and HDL-C levels, which may increase the risk of cardiovascular disease.